Earnings Releases·Nov 10, 2026, 4:15 PM ET

NextCure — Third Quarter 2026 Earnings Summary

Net loss narrowed to $6.8 million for Q3 2026 from $8.6 million in the prior year period, while cash and equivalents declined to $8.7 million from $41.8 million at year-end 2025.
Merger financing commitments with Avere Therapeutics increased to approximately $820 million to support the development of lead program AVR-001, with the combined entity expected to trade as "AVRX" on Nasdaq.
Significant restructuring was completed, including workforce reductions and asset disposals, while the LNCB74 program transitioned to LigaChem Biosciences with NextCure retaining rights to future milestones and royalties.
The SEC declared the merger registration statement effective on November 6, 2026, with a special stockholder meeting scheduled for December 9, 2026, to vote on the transaction.
Existing stockholders are expected to retain a minority ownership interest in the combined company and receive contingent value rights (CVRs) tied to legacy assets.